Oyster Therapeutics, formerly Kesmalea Therapeutics, has raised $60 million in Series A financing to advance a new generation of targeted protein degraders for neurodegenerative diseases. The financing will support the company’s lead oral, brain-penetrant tau degrader toward clinical development and further advance its proprietary SELFTAC® platform.
